Piramal Pharma Q4 Net Profit Dips 5.6% YoY

• Board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026, reporting FY net profit of ₹700.01 crore.
• Reappointed four directors including Executive Chairperson Nandini Piramal and CEO Peter DeYoung for additional 3-year terms each.
• Appointed Maneesh Sharma as Company Secretary and Compliance Officer, effective April 29, 2026, replacing interim officer.
• Changed registered office address within Mumbai and reported exceptional items of ₹92.51 crore for FY2026.